Exhibit 99.1

Acasti Pharma To Present at Biotech Showcase Conference

Laval, Québec, CANADA – January 2, 2018 – Acasti Pharma Inc. (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced that Jan D’Alvise, the company’s president and chief executive officer will present at Biotech Showcase Conference on Wednesday, January 10 at 11:00 a.m. PT in Yosemite - A of the Ballroom Level. The conference will take place at the Hilton San Francisco Union Square.

A live audio webcast of the presentation will be available under the “News & Investors” section of Acasti's website at www.acastipharma.com. A replay of the presentation will be available for 60 days following the event.

About Acasti Pharma

Acasti Pharma is a biopharmaceutical innovator advancing a potentially best-in-class cardiovascular drug, CaPre® (omega-3 phospholipid), for the treatment of hypertriglyceridemia, a chronic condition affecting an estimated one third of the U.S. population. The company’s strategy is to initially develop and commercialize CaPre for the 3 to 4 million patients in the U.S. with severe hypertriglyceridemia. Since its founding in 2008, Acasti Pharma has focused on addressing a critical market need for an effective, safe and well-absorbing omega-3 therapeutic that can make a positive impact on the major blood lipids associated with cardiovascular disease risk. For more information, visit www.acastipharma.com.

# # #

Acasti Contact:

Jan D’Alvise

Chief Executive Officer

450-686-4555

info@acastipharma.com

www.acastipharma.com

Media Contact:

Jessica Dyas

Canale Communications

619-849-5385

jessica@canalecomm.com

Investor Relations Contact:

Glen Akselrod

Bristol Capital Ltd.

(905) 326-1888 ext 10

glen@bristolir.com

Page 1 of 1